Health Advances Blog

Reflections on Healthcare & Life Sciences Innovation

Skip to content
Menu
  • Home
  • About
  • COVID-19 Impact
  • Visit Our Website
  • Contact Us

Category: European Markets

Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?
  • by healthadvances
  • Posted on August 6, 2021August 9, 2021

Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?

Read More
  • by healthadvances
  • Posted on May 6, 2020

The Changing Fortunes of Telemedicine in Europe – Past, Present, and Future beyond COVID-19

Read More
  • by healthadvances
  • Posted on April 16, 2020April 16, 2020

US SARS-CoV-2 Testing Response: What can be learned from South Korea and Germany?

Read More
  • by healthadvances
  • Posted on April 13, 2020April 20, 2020

Medtech Geographic Launch Sequences Warrant Reevaluation

Read More
  • by healthadvances
  • Posted on March 24, 2020April 13, 2020

e-Health in France: Spotlight on the National Healthcare Digitalization Strategy

Read More
  • by healthadvances
  • Posted on March 10, 2020April 13, 2020

ATTD 2020 – Transforming Diabetes Care Through Technology

Read More
  • by healthadvances
  • Posted on January 14, 2020April 13, 2020

Bridging the Gap in Clinical and Economic Evidence for Digital Health Tech in the UK

Read More
  • by healthadvances
  • Posted on October 14, 2019April 13, 2020

Key Takeaways from ESMO 2019

Read More
  • by healthadvances
  • Posted on July 23, 2019December 7, 2021

E-Health in Germany: Three New Laws Signify the Imminent Transformation to a Digitalised Healthcare System

Read More
  • by healthadvances
  • Posted on November 9, 2018April 13, 2020

Health Advances Presentation at ISPOR: Findings from the First Five Years of the NICE HST Program for Ultra Rare Conditions

Read More
  • by healthadvances
  • Posted on October 2, 2018April 13, 2020

E-Health in Germany: Rapid Progression of Digitalisation?

Read More
  • by healthadvances
  • Posted on September 18, 2018April 13, 2020

New Assessment Pathway for Invasive High-Risk Medical Devices in Germany: Balancing Market Access, Evidence and Patient Benefit

Read More
  • by healthadvances
  • Posted on August 23, 2018April 13, 2020

Disease Management Programs (DMPs) in Germany: The Importance of Guideline Inclusion for Chronic Therapies

Read More
  • by healthadvances
  • Posted on July 19, 2018April 13, 2020

The Medicines Optimisation Program in England

Read More
  • by healthadvances
  • Posted on May 3, 2018April 15, 2020

Patient Advocacy Groups as a Strategy for Orphan Drug Access in the UK

Read More
  • by healthadvances
  • Posted on April 10, 2018April 15, 2020

PCSK9 Inhibitors’ Battle for Reimbursement: Germany’s Decision and Implications in Other Countries

Read More
  • by healthadvances
  • Posted on March 13, 2018April 15, 2020

The Accelerated Access Review in the UK: Quicker Access to Innovative Drugs and Diagnostics, Medical and Digital Technologies

Read More

Stay Connected

Enter your email address to subscribe to Health Advances blog and receive notifications of new posts by email.

We use WordPress as our blog publishing platform. By entering your email address, you acknowledge that the information you provide will be transferred to WordPress for processing in accordance with their Privacy Policy and Terms.

Topics of Interest

  • Asia/APAC Markets
  • BioPharma
  • COVID-19
  • Diagnostics and Life Science Tools
  • European Markets
  • Health IT and Digital Health
  • Investors
  • Launch Excellence
  • Market Access & Health Policy
  • MedTech
  • Other

Search Our Blog

Follow Us on Social Media

  • View healthadvances’s profile on Facebook
  • View @healthadvances’s profile on Twitter
  • LinkedIn

Recent Tweets

My Tweets
This website uses cookies. You may choose to continue browsing with cookies or leave the site.

Health Advances Privacy Policy
Create a website or blog at WordPress.com
 

Loading Comments...